Dishman Carbogen Amcis Ltd. (IN:DCAL)
:DCAL
Want to see IN:DCAL full AI Analyst Report?
DCAL Stock Chart & Stats
₹255.15
-₹14.00(-4.80%)
At close: 4:00 PM EST
₹255.15
-₹14.00(-4.80%)
Day’s Range― - ―
52-Week Range₹129.00 - ₹321.15
Previous CloseN/A
Volume578.20K
Average Volume (3M)13.55K
Market Cap
₹33.11B
Enterprise Value₹52.54B
Total Cash (Recent Filing)₹5.32B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.65
Shares Outstanding156,783,100
10 Day Avg. Volume9,637
30 Day Avg. Volume13,551
Financial Highlights & Ratios
PEG Ratio-10.28
Price to Book (P/B)0.58
Price to Sales (P/S)1.25
P/FCF Ratio21.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very High Gross MarginAn 81.49% gross margin indicates durable manufacturing efficiency and pricing power in CDMO/chemical operations. High gross margins provide a structural cushion against raw-material or volume swings, enabling reinvestment in capacity and R&D and supporting margin stability over several months.
Strong Free Cash Flow GrowthNearly 100% FCF growth signals improving cash generation from operations, strengthening the company’s ability to fund capex, repay debt, or finance working-capital needs internally. Sustained FCF expansion enhances financial flexibility over a 2–6 month horizon.
Manageable Leverage And Solid Equity BaseA 58% equity ratio and 0.41 debt/equity reflect conservative balance-sheet structure. Moderate leverage supports funding of CDMO scale-up without excess refinancing risk, preserving capacity to invest through cycles and maintain supplier/customer confidence over the medium term.
Bears Say
Very Low Net Profitability And ROENet margin near zero and ROE of 0.06% show weak bottom-line returns despite high gross margins. This structural disconnect limits retained earnings, constrains shareholder returns, and signals underlying cost, SG&A, or nonoperating issues that could persist over multiple quarters.
Weak Profit-to-free-cash ConversionOnly about half of reported net income converts to free cash flow, indicating earnings are not fully translating into spendable cash. Persistent low conversion can limit self-funded growth, raise sensitivity to working-capital swings, and weaken resilience through industry cycles.
Limited Earnings Growth VisibilityAbsent EPS growth data suggests inconsistent or unclear earnings progression and limited forward visibility. For a contract manufacturing business, this hinders planning and investor confidence, making it harder to assess sustainable profit trends over the next several months.
Dishman Carbogen Amcis Ltd. News
DCAL FAQ
What was Dishman Carbogen Amcis Ltd.’s price range in the past 12 months?
Dishman Carbogen Amcis Ltd. lowest stock price was ₹129.00 and its highest was ₹321.15 in the past 12 months.
What is Dishman Carbogen Amcis Ltd.’s market cap?
Dishman Carbogen Amcis Ltd.’s market cap is ₹33.11B.
When is Dishman Carbogen Amcis Ltd.’s upcoming earnings report date?
Dishman Carbogen Amcis Ltd.’s upcoming earnings report date is Aug 12, 2026 which is in 83 days.
How were Dishman Carbogen Amcis Ltd.’s earnings last quarter?
Dishman Carbogen Amcis Ltd. released its earnings results on May 19, 2026. The company reported ₹1.39 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.39.
Is Dishman Carbogen Amcis Ltd. overvalued?
According to Wall Street analysts Dishman Carbogen Amcis Ltd.’s price is currently Overvalued.
Does Dishman Carbogen Amcis Ltd. pay dividends?
Dishman Carbogen Amcis Ltd. pays a Annually dividend of ₹0.2 which represents an annual dividend yield of N/A. See more information on Dishman Carbogen Amcis Ltd. dividends here
What is Dishman Carbogen Amcis Ltd.’s EPS estimate?
Dishman Carbogen Amcis Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dishman Carbogen Amcis Ltd. have?
Dishman Carbogen Amcis Ltd. has 156,783,100 shares outstanding.
What happened to Dishman Carbogen Amcis Ltd.’s price movement after its last earnings report?
Dishman Carbogen Amcis Ltd. reported an EPS of ₹1.39 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.399%.
Which hedge fund is a major shareholder of Dishman Carbogen Amcis Ltd.?
Currently, no hedge funds are holding shares in IN:DCAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dishman Carbogen Amcis Ltd.
Dishman Carbogen Amcis Limited provides contract research and manufacturing services to the pharmaceutical industry worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It also manufactures and supplies bulk drugs, intermediates, phase transfer catalysts, quaternary ammonium compounds, phosphoranes, wittig reagents, vitamin D products, fine chemicals, hand and body wash, sanitisers, antiseptics, and various pharmaceutical and cosmetic-related products, as well as generic and highly potent active pharmaceutical ingredients. The company was incorporated in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Jubilant Ingrevia Ltd.
―
Panacea Biotec Limited
―
Syngene International Ltd.
―